<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MICRO-K EXTENCAPS - potassium chloride capsule, extended release </strong><br><strong>MICRO-K 10 EXTENCAPS - potassium chloride capsule, extended release </strong><br>Ther-Rx Corporation<br></p></div>
<h1>Micro-K<span class="Sup">®</span> Extencaps®<span class="Sup"></span><br>Micro-K<span class="Sup">®</span> 10 Extencaps<span class="Sup">®</span><br>(Potassium Chloride Extended-Release Capsules, USP)
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">U.S. Patent No. 4,259,315<br>Rx Only <br>P3511-4    06/05
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">Micro-K<span class="Sup">®</span> Extencaps<span class="Sup">®</span> Capsules and Micro-K<span class="Sup">®</span> 10 Extencaps<span class="Sup">®</span> Capsules are oral dosage forms of microencapsulated potassium chloride containing 600 and 750 mg, respectively, of potassium chloride, USP, equivalent to 8 and 10 mEq of potassium, respectively.
</p>
<p>Dispersibility of potassium chloride (KCI) is accomplished by microencapsulation and a dispersing agent. The resultant flow characteristics of the KCI microcapsules and the controlled release of K<span class="Sup">+</span> ions by the microcapsular membrane are intended to avoid the possibility that excessive amounts of KCI can be localized at any point on the mucosa of the gastrointestinal tract.
</p>
<p>Each crystal of KCI is microencapsulated by a patented process with an insoluble polymeric coating which functions as a semi-permeable membrane; it allows for the controlled release of potassium and chloride ions over an eight-to ten-hour period. Fluids pass through the membrane and gradually dissolve the potassium chloride within the microcapsules. The resulting potassium chloride solution slowly diffuses outward through the membrane. Micro-K<span class="Sup">®</span> and Micro-K<span class="Sup">®</span> 10 are electrolyte replenishers. The chemical name of the active ingredient is potassium chloride and the structural formula is KCI. Potassium chloride, USP, occurs as a white, granular powder or as colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol.
</p>
<p>The inactive ingredients are edible ink, ethylcellulose, FD&amp;C Blue No. 2 aluminum lake, FD&amp;C Yellow No. 6, gelatin, magnesium stearate, sodium lauryl sulfate, titanium dioxide. May contain FD&amp;C Red No. 40 and Yellow No. 6 aluminum lakes.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes, including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal, and smooth muscle, and the maintenance of normal renal function.
</p>
<p>The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane.
</p>
<p>Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day.
</p>
<p>Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops slowly as a consequence of therapy with diuretics, primary or secondary hyperaldosteronisms, <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, especially if associated with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Potassium depletion due to these causes is usually accompanied by a concomitant loss of chloride and is manifested by <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>. Potassium depletion may produce <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and in advanced cases, <span class="product-label-link" type="condition" conceptid="4193951" conceptname="Flaccid paralysis">flaccid paralysis</span> and/or impaired ability to concentrate urine.
</p>
<p>If potassium depletion associated with <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span> cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.
</p>
<p>In rare circumstances (e.g., patients with <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">renal tubular acidosis</span>) potassium depletion may be associated with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4253927" conceptname="Hyperchloremia">hyperchloremia</span>. In such patients potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, potassium citrate, potassium acetate, or potassium gluconate.
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span> WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS.
</p>
<ol class="Arabic">
<li>For the treatment of patients with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> with or without <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>, in <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis intoxications</span>, and in patients with hypokalemic <span class="product-label-link" type="condition" conceptid="73184" conceptname="Familial periodic paralysis">familial periodic paralysis</span>.  If <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.
</li>
<li>For the prevention of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in patients who would be at particular risk if <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> were to develop e.g., digitalized patients or patients with significant <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> with <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, states of aldosterone excess with normal renal function, potassium-losing <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span>, and certain diarrheal states.
</li>
</ol>
<p>The use of potassium salts in patients receiving diuretics for uncomplicated <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">Potassium supplements are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> since a further increase in serum potassium concentration in such patients can produce <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> may complicate any of the following conditions: <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>, systemic <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> such as <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic acidosis</span>, acute <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, extensive tissue breakdown as in severe <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>, or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene, amiloride) (see <span class="Bold"><a href="#s24">OVERDOSAGE</a></span>).
</p>
<p>Controlled-release formulations of potassium chloride have produced <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulceration</span> in certain cardiac patients with esophageal compression due to an enlarged left atrium. Potassium supplementation, when indicated in such patients, should be given as a liquid preparation.
</p>
<p>All solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological (e.g., <span class="product-label-link" type="condition" conceptid="4142033" conceptname="Diabetic gastroparesis">diabetic gastroparesis</span>) or pharmacologic (use of anticholinergic agents or other agents with anticholineric properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in capsule passage through the gastrointestinal tract.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> (see OVERDOSAGE)
</h2>
<p class="First">In patients with impaired mechanisms for excreting potassium, the administration of potassium salts can produce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> can develop rapidly and be asymptomatic. The use of potassium salts in patients with chronic <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustments.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-6.2"></a><p></p>
<h2>Interaction with Potassium-Sparing Diuretics
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene, or amiloride), since the simultaneous administration of these agents can produce severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-6.3"></a><p></p>
<h2>Interaction with Angiotensin Converting Enzyme Inhibitors
</h2>
<p class="First">Angiotensin converting enzyme (ACE) inhibitors (e.g., captopril, enalapril) will produce some potassium retention by inhibiting aldosterone production. Potassium supplements should be given to patients receiving ACE inhibitors only with close monitoring.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-6.4"></a><p></p>
<h2>Gastrointestinal Lesions
</h2>
<p class="First">Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract. Based on spontaneous adverse reaction reports, enteric-coated preparations of potassium chloride are associated with an increased frequency of small bowel lesions (40 - 50 per 100,000 patient years) compared to sustained-release wax matrix formulations (less than one per 100,000 patient years). Because of the lack of extensive marketing experience with microencapsulated products, a comparison between such products and wax matrix or enteric-coated products is not available. Micro-K<span class="Sup">®</span> Extencaps<span class="Sup">®</span> and Micro-K<span class="Sup">®</span> 10 Extencaps<span class="Sup">®</span> are microencapsulated capsules formulated to provide a controlled rate of release of microencapsulated potassium chloride and thus to minimize the possibility of high local concentration of potassium near the gastrointestinal wall.
</p>
<p>Prospective trials have been conducted in normal human volunteers in which the upper gastrointestinal tract was evaluated by endoscopic inspection before and after one week of solid oral potassium chloride therapy. The ability of this model to predict events occurring in usual clinical practice is unknown. Trials which approximated usual clinical practice did not reveal any clear differences between the wax matrix and microencapsulated dosage forms. In contrast, there was a higher incidence of gastric and duodenal lesions in subjects receiving a high dose of a wax matrix controlled-release formulation under conditions which did not resemble usual or recommended clinical practice (i.e., 96 mEq per day in divided doses of potassium chloride administered to fasted patients, in the presence of an anticholinergic drug to delay gastric emptying). The upper gastrointestinal lesions observed by endoscopy were asymptomatic and were not accompanied by evidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (hemoccult testing). The relevance of these findings to the usual conditions (i.e., non-fasting, no anticholinergic agent, smaller doses) under which controlled-release potassium chloride products are used is uncertain; epidemiologic studies have not identified an elevated risk, compared to microencapsulated products, for upper gastrointestinal lesions in patients receiving wax matrix formulations. Micro-K<span class="Sup">®</span> Extencaps<span class="Sup">®</span> and Micro-K<span class="Sup">®</span> 10 Extencaps<span class="Sup">®</span> should be discontinued immediately and the possibility of ulceration, obstruction or perforation considered if severe <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> occur.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> in patients with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> should be treated with an alkalinizing potassium salt such as potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, potassium citrate, potassium acetate, or potassium gluconate.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s12"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS:
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s13"></a><a name="section-7.1"></a><p></p>
<h2>General
</h2>
<p class="First">The diagnosis of potassium depletion is ordinarily made by demonstrating <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in a patient with a clinical history suggesting some cause for potassium depletion. In interpreting the serum potassium level, the physician should bear in mind that acute <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span> per se can produce <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in the absence of a deficit in total body potassium, while <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acute acidosis</span> per se can increase the serum potassium concentration into the normal range even in the presence of a reduced total body potassium. The treatment of potassium depletion, particularly in the presence of cardiac disease, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, or <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, requires careful attention to acid-base balance and appropriate monitoring of serum electrolytes, the electrocardiogram, and the clinical status of the patient.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s14"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients
</h2>
<p class="First">Physicians should consider reminding the patient of the following: To take each dose with meals and with a full glass of water or other suitable liquid. To take each dose without crushing, chewing, or sucking the capsules. To take this medicine following the frequency and amount prescribed by the physician. This is especially important if the patient is also taking diuretics and/or digitalis preparations. To check with the physician if there is trouble swallowing capsules or if the capsules seem to stick in the throat.
</p>
<p>To check with the physician at once if <span class="product-label-link" type="condition" conceptid="4103703" conceptname="Melena">tarry stools</span> or other evidence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> is noticed.
</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s15"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests
</h2>
<p class="First">Regular serum potassium determinations are recommended, especially in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or <span class="product-label-link" type="condition" conceptid="192279" conceptname="Diabetic renal disease">diabetic nephropathy</span>. When blood is drawn for analysis of plasma potassium it is important to recognize that artifactual elevations can occur after improper venipuncture technique or as a result of in vitro <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> of the sample.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s16"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions
</h2>
<p class="First">Potassium-sparing diuretics, angiotensin converting enzyme inhibitors (see <span class="Bold"><a href="#s6">WARNINGS</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s17"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Carcinogenicity, mutagenicity and fertility studies in animals have not been performed. Potassium is a normal dietary constituent.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s18"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s19"></a><a name="section-7.6.1"></a><p></p>
<p class="First"><span class="Bold">Teratogenic Effects: Category C</span> Animal reproduction studies have not been conducted with Micro-K<span class="Sup">®</span>. It is unlikely that potassium supplementation that does not lead to <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> would have an adverse effect on the fetus or would affect reproductive capacity.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s20"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers
</h2>
<p class="First">The normal potassium ion content of human milk is about 13 mEq per liter. Since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s21"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s22"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use
</h2>
<p class="First">Clinical studies of potassium chloride extended-release capsules did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s23"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">One of the most severe adverse effects is <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (see <span class="Bold"><a href="#s5">CONTRAINDICATIONS</a></span>, <span class="Bold"><a href="#s6">WARNINGS</a></span>, and <span class="Bold"><a href="#s24">OVERDOSAGE</a></span>). <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> and ulceration have been reported in patients treated with Micro-K<span class="Sup">®</span> Extencaps<span class="Sup">®</span> (see <span class="Bold"><a href="#s5">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#s6">WARNINGS</a></span>). In addition to <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> and ulceration, perforation and obstruction have been reported in patients treated with other solid KCI dosage forms, and may occur with Micro-K<span class="Sup">®</span> Extencaps<span class="Sup">®</span>.
</p>
<p>The most common adverse reactions to the oral potassium salts are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. These symptoms are due to irritation of the gastrointestinal tract and are best managed by taking the dose with meals, or reducing the amount taken at one time. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> has been reported rarely with potassium preparations.
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s24"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. However, if excretory mechanisms are impaired or if potassium is administered too rapidly intravenously, potentially fatal <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> can result (see <span class="Bold"><a href="#s5">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#s6">WARNINGS</a></span>). It is important to recognize that <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5 - 8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-waves, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of ST segment, and prolongation of the QT interval). Late manifestations include muscle <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> from <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> (9 - 12 mEq/L).
</p>
<p>Treatment measures for <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> include the following: (1) elimination of foods and medications containing potassium and of any agents with potassium-sparing properties; (2) intravenous administration of 300 to 500 mL/hr of 10% dextrose solution containing 10 to 20 units of crystalline insulin per 1,000 mL; (3) correction of <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, if present, with intravenous sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>; (4) use of exchange resins, hemodialysis, or peritoneal dialysis. In treating <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>.
</p>
<p>The extended release feature means that absorption and toxic effects may be delayed for hours. Consider standard measures to remove any unabsorbed drug.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s25"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">The usual dietary intake of potassium by the average adult is 50 to 100 mEq per day. Potassium depletion sufficient to cause <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> usually requires the loss of 200 mEq or more of potassium from the total body store.
</p>
<p>Dosage must be adjusted to the individual needs of each patient. The dose for the prevention of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> is typically in the range of 20 mEq per day. Doses of 40 to 100 mEq per day or more are used for the treatment of potassium depletion. Dosage should be divided if more than 20 mEq per day is given such that no more than 20 mEq is given in a single dose. Because of the potential for <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span> (see <span class="Bold"><a href="#s6">WARNINGS</a></span>), Micro-K<span class="Sup">®</span> Extencaps<span class="Sup">®</span> should be taken with meals and with a full glass of water or other liquid.
</p>
<p>Patients who have difficulty swallowing capsules may sprinkle the contents of the capsule onto a spoonful of soft food. The soft food, such as applesauce or pudding, should be swallowed immediately without chewing and followed with a glass of cool water or juice to ensure complete swallowing of the microcapsules. The food used should not be hot and should be soft enough to be swallowed without chewing. Any microcapsule/food mixture should be used immediately and not stored for future use.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s26"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">Micro-K<span class="Sup">®</span> Extencaps containing 600 mg of microencapsulated potassium chloride (equivalent to 8 mEq K), are <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> orange capsules, imprinted "Micro-K" on the cap and "Ther-Rx 010" on the body, packaged as follows: <br><span class="Bold">NDC</span> 64011-010-04 bottle of 100 capsules<br><span class="Bold">NDC</span> 64011-010-08 bottle of 500 capsules<br><span class="Bold">NDC</span> 64011-010-11 Dis-Co® unit dose packages of 100 capsules
</p>
<p>Micro-K<span class="Sup">®</span> 10 Extencaps<span class="Sup">®</span> containing 750 mg of microencapsulated potassium chloride (equivalent to 10 mEq K), are <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> orange and opaque white capsules, imprinted "Micro-K 10" on the cap and "Ther-Rx 009" on the body, packaged as follows:<br><span class="Bold">NDC</span> 64011-009-04 bottle of 100 capsules <br><span class="Bold">NDC</span> 64011-009-08 bottle of 500 capsules<br><span class="Bold">NDC</span> 64011-009-11 Dis-Co® unit dose packages of 100 capsules
</p>
<p><span class="Bold">Store at controlled room temperature 20°-25°C (68°-77°F).</span></p>
<p>Dispense in tight container.
</p>
<p>Mktd. by Ther-Rx Corp. St. Louis, MO 63044
</p>
<p>06/05<br>P3511-4
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s30"></a><a name="section-12"></a><p></p>
<p class="First">NDC 64011-010-04 100 Capsules</p>
<p><span class="Bold">Micro-K<br>Extencaps</span><br>(potassium chloride)</p>
<p>(600 mg)<br>8 mEq K</p>
<p>Rx Only Ther-Rx Corporation</p>
<div class="Figure">
<a name="f01"></a><img alt="8 mEq 100 ct" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb128705-d8c7-4341-a976-d8fd7371df6d&amp;name=micro-k1.jpg">
</div>
<p>NDC 64011-010-08 500 Capsules</p>
<p><span class="Bold">Micro-K<br>Extencaps</span><br>(potassium chloride)</p>
<p>(600 mg)<br>8 mEq K</p>
<p>Rx Only Ther-Rx Corporation</p>
<div class="Figure">
<a name="f02"></a><img alt="8 mEq 500 ct" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb128705-d8c7-4341-a976-d8fd7371df6d&amp;name=micro-k2.jpg">
</div>
<p>Dis-Co<br>NDC 64011-010-11</p>
<p><span class="Bold">Micro-K<br>Extencaps</span><br>(potassium chloride)</p>
<p>(600 mg)<br>8 mEq K</p>
<p>Rx Only<br>100 Capsules (Unit Dose Pack)<br>Ther-Rx Corporation</p>
<div class="Figure">
<a name="f03"></a><img alt="8 mEq carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb128705-d8c7-4341-a976-d8fd7371df6d&amp;name=micro-k3.jpg">
</div>
<p>NDC 64011-009-04 100 Capsules</p>
<p><span class="Bold">Micro-K 10<br>Extencaps</span><br>(potassium chloride)</p>
<p>(750 mg)<br>10 mEq K</p>
<p>Rx Only Ther-Rx Corporation</p>
<div class="Figure">
<a name="f04"></a><img alt="10 mEq 100 ct" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb128705-d8c7-4341-a976-d8fd7371df6d&amp;name=micro-k4.jpg">
</div>
<p>NDC 64011-009-08 500 Capsules</p>
<p><span class="Bold">Micro-K 10<br>Extencaps</span><br>(potassium chloride)</p>
<p>(750 mg)<br>10 mEq K</p>
<p>Rx Only Ther-Rx Corporation</p>
<div class="Figure">
<a name="f05"></a><img alt="10 mEq 500 ct" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb128705-d8c7-4341-a976-d8fd7371df6d&amp;name=micro-k5.jpg">
</div>
<p>Dis-Co<br>NDC 64011-009-11</p>
<p><span class="Bold">Micro-K<br>Extencaps</span><br>(potassium chloride)</p>
<p>(750 mg)<br>10 mEq K</p>
<p>Rx Only<br>100 Capsules (Unit Dose Pack)<br>Ther-Rx Corporation</p>
<div class="Figure">
<a name="f06"></a><img alt="10 mEq carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb128705-d8c7-4341-a976-d8fd7371df6d&amp;name=micro-k6.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MICRO-K EXTENCAPS 		
					</strong><br><span class="contentTableReg">potassium chloride capsule, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64011-010</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POTASSIUM CHLORIDE</strong> (POTASSIUM CATION) </td>
<td class="formItem">POTASSIUM CHLORIDE</td>
<td class="formItem">600 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLCELLULOSE (100 CPS)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Micro;k;Ther;Rx;010
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64011-010-04</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64011-010-08</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64011-010-11</td>
<td class="formItem">100  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018238</td>
<td class="formItem">08/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MICRO-K 10 EXTENCAPS 		
					</strong><br><span class="contentTableReg">potassium chloride capsule, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64011-009</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POTASSIUM CHLORIDE</strong> (POTASSIUM CATION) </td>
<td class="formItem">POTASSIUM CHLORIDE</td>
<td class="formItem">750 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLCELLULOSE (100 CPS)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (orange) , WHITE (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Micro;K;Ther;Rx;009
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64011-009-04</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64011-009-08</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64011-009-11</td>
<td class="formItem">100  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018238</td>
<td class="formItem">08/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Ther-Rx Corporation
							(055041706)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>KV Pharmaceutical (006291405)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">KV Pharmaceutical</td>
<td class="formItem"></td>
<td class="formItem">161097225</td>
<td class="formItem">manufacture</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">KV Pharmaceutical</td>
<td class="formItem"></td>
<td class="formItem">034060843</td>
<td class="formItem">analysis</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">KV Pharmaceutical</td>
<td class="formItem"></td>
<td class="formItem">152053658</td>
<td class="formItem">manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cc23b098-1c7c-4c96-a18b-39a80b9b68e1</div>
<div>Set id: cb128705-d8c7-4341-a976-d8fd7371df6d</div>
<div>Version: 3</div>
<div>Effective Time: 20091221</div>
</div>
</div> <div class="DistributorName">Ther-Rx Corporation</div></p>
</body></html>
